PTCT Stock Analysis: Buy, Sell, or Hold?
PTCT - PTC Therapeutics, Inc.
$65.73
-0.40 (-0.60%)
▼
5d:
-1.04%
30d:
-3.61%
90d:
-16.33%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 05, 2026
Get Alerted When PTCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
🚀 STRONG BUY: PTCT shows excellent value with unusually cheap options (IV 16th percentile) and market pricing in only 1.4% annual growth despite strong fundamentals. High conviction opportunity.
🚀 STRONG BUY: PTCT shows excellent value with unusually cheap options (IV 16th percentile) and market pricing in only 1.4% annual growth despite strong fundamentals. High conviction opportunity.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$85.12
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$52.85
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PTCT is currently trading at $65.73, which is considered fair relative to its 30-day fair value range of $64.56 to $68.71. The stock's valuation (Forward PE: 27.2) is in line with its historical norms (26.1). At these levels, the market is pricing in 1.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PTCT is in a downtrend. The price is currently testing key support at $64.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PTCT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $87.57 (+32.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PTCT is in a downtrend. The price is currently testing key support at $64.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PTCT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $87.57 (+32.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$64.56 -
$68.71
Company Quality Score
57/100
(HOLD)
Options IV Signal
16th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
87.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 16th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 32.4% below Wall St target ($87.57)
- NEUTRAL: Market pricing in 1.4% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$64.56 -
$68.71
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$5.37
(8.2%)
Support & Resistance Levels
Support Level
$64.00
Resistance Level
$69.02
Current Trend
Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
27.21
Wall Street Target
$87.57
(+32.4%)
Revenue Growth (YoY)
-22.7%
Profit Margin
39.4%
Valuation Premium vs History
+1.4% premium
PE vs Historical
27.2 vs 26.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.4%
(market-implied from PE analysis)
1-Year Target
$67.06
(+1%)
2-Year Target
$67.99
(+3%)
3-Year Target
$68.95
(+4%)
3-Yr Target (if PE normalizes)
(PE: 27→26)
PE COMPRESSION
$66.12
(0%)
Earnings growth offset by PE compression
📈
Valuation based on Current Earnings
Trailing PE: 7.61 | Current EPS (TTM): $8.58
Bull Case
$35.91
(-46%)
Analyst growth -50.0%, PE expands to 8.4
Base Case
$32.65
(-51%)
Market implied -50.0%, PE stable at 7.6
Bear Case
$44.40
(-33%)
Severe decline -20.0%, PE contracts to 6.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: March 30, 2026 1:41 PM ET
Data refreshes hourly during market hours. Next update: 2:41 PM
Data refreshes hourly during market hours. Next update: 2:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PTCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Matthew B Klein
SELL
2662 shares
2026-03-12
Stephanie Okey
SELL
15167 shares
2026-03-10
Lee Scott Golden
SELL
10000 shares
2026-03-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 53 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 60 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 42 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 57 HOLD |
